Cardanol monoene
Based on 1 Customer Validation
Cardanol monoene (Cardanol C15:1) is a phenolic compound which can be found in cashew nut shell liquid. Cardanol monoene can inhibit cancer cells proliferation, migration, cause S phase arrest, induce apoptosis, ROS production and mitochondrial depolarization. Cardanol monoene downregulates MMP-2, MMP-9, cyclinA1 expression, regulates CDK2, p53, Bax, cytochrome c, cleaved caspase-3, cleaved PARP, Apaf-1 expression and Bax/Bcl-2 ratio. Cardanol monoene shows weak DPPH radical scavenging activity and AChE inhibition activity. Cardanol monoene is lethal to Artemia salina nauplii. Cardanol monoene. Cardanol monoene can be used for the research of cancer, infection and inflamation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.51%
- CAS. Nr.: 501-26-8
- Formel: C21H34O
- Molecular Weight:302.49
-
Speicherung:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-13426S
Roxadustat-d5Stable Isotope -
HY-126983
6',7'-EpoxybergamottinFungal Metabolite -
HY-W013331
DeoxyartemisininAnti-inflammatory and Analgesic Agent -
HY-113612A
Cytostatin sodiumPP2A Inhibitor -
HY-N12261
Benastatin BGST Inhibitor -
HY-B0223S2
Albendazole-d7Stable Isotope -
HY-N2687
5-n-TricosylresorcinolFlavonoid Compound -
HY-125322
Reveromycin CPolyketide
Alle Caspase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
MMP-2 |
MMP-9 |
cdk2/cyclin A |
Caspase 3 |
Bcl-2 |
Bax |
AChE |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
9.09 μg/mL
Compound: 1, cardanol C15:1
|
Growth inhibition of human A549 cells after 2 days by SRB assay
Growth inhibition of human A549 cells after 2 days by SRB assay
|
[PMID: 9677265] |
| CCD-18Co | IC50 |
54.58 μg/mL
Compound: 1, cardanol C15:1
|
Growth inhibition of human CCD-18Co cells after 2 days by SRB assay
Growth inhibition of human CCD-18Co cells after 2 days by SRB assay
|
[PMID: 9677265] |
| HCT-15 | IC50 |
29.9 μg/mL
Compound: 1, cardanol C15:1
|
Growth inhibition of human HCT15 cells after 2 days by SRB assay
Growth inhibition of human HCT15 cells after 2 days by SRB assay
|
[PMID: 9677265] |
| HT1197 | IC50 |
18.81 μg/mL
Compound: 1, cardanol C15:1
|
Growth inhibition of human HT1197 cells after 2 days by SRB assay
Growth inhibition of human HT1197 cells after 2 days by SRB assay
|
[PMID: 9677265] |
| MCF7 | IC50 |
5.56 μg/mL
Compound: 1, cardanol C15:1
|
Growth inhibition of human MCF7 cells after 2 days by SRB assay
Growth inhibition of human MCF7 cells after 2 days by SRB assay
|
[PMID: 9677265] |
| SK-OV-3 | IC50 |
12.9 μg/mL
Compound: 1, cardanol C15:1
|
Growth inhibition of human SKOV3 cells after 2 days by SRB assay
Growth inhibition of human SKOV3 cells after 2 days by SRB assay
|
[PMID: 9677265] |
In Vitro
Cardanol monoene (2.5-40 μM; 24-48 h) inhibits human M14 melanoma cell proliferation with IC50 values of 23.15 ± 2.42 μM at 24 h and 12.30 ± 1.67 μM at 48 h, acting in a dose-dependent and time-dependent manner[1].
Cardanol monoene (10-50 μM; 2 weeks) dose-dependently reduces the colony-formation ability of human M14 melanoma cells, with 40 μM treatment lowering efficiency to 5.46% over 7 days[1].
Cardanol monoene (10-40 μM; 48 h) dose-dependently inhibits human M14 melanoma cell migration over 48 h by down-regulating MMP-2 and MMP-9 protein expression[1].
Cardanol monoene (10-40 μM; 24 h) induces dose-dependent S phase arrest in human M14 melanoma cells after 24 h treatment, reducing cyclinA1 mRNA expression and increasing CDK2 mRNA expression to inhibit cell proliferation[1].
Cardanol monoene (10-50 μM; 24-48 h) induces dose-dependent caspase-mediated apoptosis in human M14 melanoma cells via up-regulating pro-apoptotic proteins (p53, Bax, cytochrome c, cleaved caspase-3, cleaved PARP, Apaf-1), increasing the Bax/Bcl-2 ratio, and down-regulating anti-apoptotic Bcl-2, with 40 μM treatment causing 43.46% apoptotic cells after 24 h[1].
Cardanol monoene (10-40 μM; 24 h) dose-dependently increases intracellular ROS levels in human M14 melanoma cells after 24 h treatment, with 40 μM causing a 65.27% increase relative to control[1].
Cardanol monoene (10-40 μM; 24 h) dose-dependently induces mitochondrial depolarization in human M14 melanoma cells after 24 h treatment, with 40 μM reducing the red/green JC-1 fluorescence ratio to 50.37% of control[1].
Cardanol monoene (40 μM; 24 h) alters the expression of 2527 genes in human M14 melanoma cells, with DEGs enriched in cancer-related pathways including Pathways in cancer, PI3K-Akt, MAPK, and p53 signaling pathways[1].
Cardanol monoene shows weak DPPH radical scavenging and AChE inhibition activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human M14 melanoma cells
-
Concentration:2.5, 5, 10, 20, 30, 40 μM
-
Incubation Time:24 h; 48 h
-
Result:Inhibited M14 cell growth in a dose-dependent and time-dependent manner.
Reached IC50 values of 23.15 ± 2.42 μM after 24 h and 12.30 ± 1.67 μM after 48 h of treatment.
-
Cell Line:human M14 melanoma cells
-
Concentration:10, 20, 30, 40 μM
-
Incubation Time:48 h
-
Result:Dose-dependently reduced M14 cell migration ability, with wound gap size increasing as cardanol monoene concentration increased.
Dose-dependently down-regulated the expression levels of MMP-2 and MMP-9 proteins.
-
Cell Line:human M14 melanoma cells
-
Concentration:10, 20, 30, 40 μM
-
Incubation Time:24 h
-
Result:Induced dose-dependent S phase arrest: increased the proportion of cells in S phase from 16.1% (control) to 37.9% (40 μM).
Reduced cyclinA1 mRNA expression and increased CDK2 mRNA expression via Real Time qPCR.
-
Cell Line:human M14 melanoma cells
-
Concentration:10, 20, 30, 40, 50 μM (AO/EB, Hoechst 33258 staining); 10, 20, 30, 40 μM (Annexin V-FITC/PI staining, western blotting); 30 μM (apoptosis inhibition assay with Z-VAD-FMK (HY-16658B))
-
Incubation Time:24 h (Annexin V-FITC/PI staining, western blotting, apoptosis inhibition assay); 24 h, 48 h (AO/EB, Hoechst 33258 staining)
-
Result:Dose-dependently increased M14 cell apoptosis rate; raised the proportion of early and late apoptotic cells to 43.46% with 40 μM treatment, compared to 1.85% in the control.
Reduced cardanol monoene (30 μM)-induced M14 cell apoptosis ratio from 30.56% to 13.17% when combined with 40 μM Z-VAD-FMK.
Induced apoptotic morphological changes including nuclear condensation, bright staining, and fragmentation, which were reduced by Z-VAD-FMK treatment.
Dose-dependently up-regulated the expression of p53, cytochrome c, cleaved caspase-3, cleaved PARP, and Apaf-1, increased the Bax/Bcl-2 ratio, and down-regulated Bcl-2 expression at 20, 30, 40 μM.
Increased cytochrome c release from mitochondria to cytosol in a dose-dependent manner.
Elevated mRNA expression levels of Bax, p53, and p21, down-regulated Bcl-2 mRNA expression, and increased the Bax/Bcl-2 ratio dose-dependently via Real Time qPCR.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Artemia salina nauplii[2]
-
Dosage:1, 10, 100, 1000 ppm
-
Administration:24 h
-
Result:Showed an LC50 of 43,186.00 ± 1991.00 μg/mL.
- RNA extraction experimental
- Research Protocol for Infectious Diseases
- Mitochondrial membrane-potential fluorescent assay
- Annexin V plus membrane-impermeant dye apoptosis staining
- Cell migration
- BrdU Incorporation Assay
- ROS/oxidative-stress fluorescent staining
- Protocol for Cell Cycle
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- Mitochondrial membrane-potential and mitochondrial mass staining
- Apoptosis Solutions
Chemical Information
-
CAS. Nr. 501-26-8
-
Appearance Oil
-
Molecular Weight 302.49
-
Formel C21H34O
-
Color Colorless to light yellow
-
SMILES
OC1=CC=CC(CCCCCCC/C=C\CCCCCC)=C1
-
Synonyms
Cardanol C15:1
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (330.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (274 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Su WC, et al. Mitochondria-Associated Apoptosis in Human Melanoma Cells Induced by Cardanol Monoene from Cashew Nut Shell Liquid. J Agric Food Chem. 2017;65(28):5620-5631. [Content Brief]
[2]. Rodrigues Valério RB, et al. Unsaturation-Driven Modulation of Antioxidant and Acetylcholinesterase Inhibitory Activities of Cardanol Derivatives. Bioengineering (Basel). 2025;12(12):1316. Published 2025 Dec 1. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3059 mL | 16.5295 mL | 33.0589 mL | 82.6474 mL |
| 5 mM | 0.6612 mL | 3.3059 mL | 6.6118 mL | 16.5295 mL | |
| 10 mM | 0.3306 mL | 1.6529 mL | 3.3059 mL | 8.2647 mL | |
| 15 mM | 0.2204 mL | 1.1020 mL | 2.2039 mL | 5.5098 mL | |
| 20 mM | 0.1653 mL | 0.8265 mL | 1.6529 mL | 4.1324 mL | |
| 25 mM | 0.1322 mL | 0.6612 mL | 1.3224 mL | 3.3059 mL | |
| 30 mM | 0.1102 mL | 0.5510 mL | 1.1020 mL | 2.7549 mL | |
| 40 mM | 0.0826 mL | 0.4132 mL | 0.8265 mL | 2.0662 mL | |
| 50 mM | 0.0661 mL | 0.3306 mL | 0.6612 mL | 1.6529 mL | |
| 60 mM | 0.0551 mL | 0.2755 mL | 0.5510 mL | 1.3775 mL | |
| 80 mM | 0.0413 mL | 0.2066 mL | 0.4132 mL | 1.0331 mL | |
| 100 mM | 0.0331 mL | 0.1653 mL | 0.3306 mL | 0.8265 mL |
Cardanol monoene Related Classifications
HY-119979 Related Classifications
Powered by Bioz
Keywords